Shots:
- Imaging, precision diagnostics, and targeted therapies are among the many ways radiopharmaceuticals improve patient outcomes and meet unmet healthcare needs
- In 2024, the global radiopharmaceuticals market was valued at $6.74B and is envisioned to grow to $13.67B by 2033, exhibiting a CAGR of 8.2% from 2024 to 2033. Lilly ranks first in our list with a market cap of 783.76B, followed by Novartis ($233.78B) and RayzeBio ($120.16B) respectively
- PharmaShots brings a condensed report on the Top 20 Radiopharmaceutical Companies of 2025, based on market cap
20. Cellectar Biosciences
Market Cap: 16.59M
Founded Year: 1996
Total Employees: 11
Headquarters: New Jersey, United States
Stock Exchange: NASDAQ
- Cellectar Biosciences is a late-stage biopharmaceutical company known for developing cancer therapies leveraging its proprietary Phospholipid Drug Conjugate (PDC) delivery platform
- The company’s lead candidate Iopofosine is under development for various oncology indications
- In November 2024, Cellectar Biosciences and NorthStar Medical Radioisotopes entered into a strategic partnership for the Supply of Actinium-225
19. Oncoinvent
Market Cap: 18.09M
Founded Year: 2010
Total Employees: 35
Headquarters: Oslo, Norway
Stock Exchange: FRA
- Oncoinvent is a radiopharmaceutical company focused on developing targeted radiation therapies for the treatment of cancer
- Oncoinvent’s lead candidate, Radspherin, is an alpha-radiation therapy used to treat cancers that have spread to body cavities
- In December 2024, Oncoinvent collaborated with ARTBIO on radiopharma laboratory facilities
18. Radiopharm Theranostics
Market Cap: 38.45M
Founded Year: 2021
Total Employees: 20
Headquarters: Sydney, Australia
Stock Exchange: NASDAQ
- Radiopharm Theranostics is a biotechnology company specializing in the development of radiopharmaceuticals for the diagnosis and treatment of unmet medical needs
- RAD 101 is the company’s lead asset, currently being evaluated in the P-II study for brain mets
- In December 2024, Radiopharm Theranostics entered a strategic co-development partnership with Lantheus to advance developments of radiopharmaceuticals in Australia
17. OncoTherapy Science
Market Cap: 48.74M
Founded Year: 2001
Total Employees: 54
Headquarters: Kawasaki City, Japan
Stock Exchange: TYO
- OncoTherapy Science is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer therapies
- OncoTherapy’s asset OTSA101 is being evaluated in the P-I study for Synovial Sarcoma in Japan
- In 2024, the company completed the enrollment for the P-I study of OTSA101 and confirmed the safety and tolerability of radioisotope-conjugated OTSA101 in refractory, relapsed, and/or advanced synovial sarcoma patients
16. Actinium Pharmaceuticals
Market Cap: 58.34M
Founded Year: 2000
Total Employees: 37
Headquarters: New York, United States
Stock Exchange: NYSE
- Actinium Pharmaceuticals is a biotechnology company focused on developing Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies for cancer
- Actinium’s lead candidate Actimab-A is under development for relapsed/refractory AML and myeloid malignancies
- In July 2024, Actinium reported the IND application clearance by the US FDA to study Iomab-ACT for targeted conditioning before a bone marrow transplant, in patients with sickle cell disease
15. Perseus Proteomics
Market Cap: 93.02M
Founded Year: 2001
Total Employees: 25
Headquarters: Tokyo, Japan
Stock Exchange: TYO
- Perseus Proteomics is a biotechnology company focused on advancing the field of proteomics to better understand disease mechanisms and develop therapeutic antibodies
- The company is developing its radiopharmaceutical candidate PPMX-T002 for the treatment of solid tumor
- In October 2024, Perseus Proteomics presented a presentation of PPMX-T002 at the EANM’24 annual congress
14. Dongwha Pharmaceutical
Market Cap: 117.1M
Founded Year: 1897
Total Employees: 816
Headquarters: Seoul, South Korea
Stock Exchange: KRX
- Dongwha Pharmaceutical is a South Korean pharmaceutical company that specializes in the development, manufacturing, and distribution of a wide range of pharmaceutical products
- The company has one marketed radiopharmaceutical product Milican injection used in the treatment of hepatocellular carcinoma and hemophiliac arthritis
- In September 2024, Dongwha Pharmaceutical acquired Hironic, an aesthetic medical device manufacturer
13. Clarity Pharmaceuticals
Market Cap: 459.97M
Founded Year: 2010
Total Employees: 50
Headquarters: New South Wales, Australia
Stock Exchange: ASX
- Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing targeted radio therapies in oncology
- The company’s lead radiopharmaceutical candidate SAR-bisPSMA is being developed for prostate cancer
- In November 2024, the company reported the dosing of the first 2 participants with Cu-64 SAR-bisPSMA in Co-PSMA study
12. Eckert & Ziegler AG
Market Cap: 1.21B
Founded Year: 1997
Total Employees: 1,143
Headquarters: Berlin, Germany
Stock Exchange: ETR
- Eckert & Ziegler AG is focused on the development, manufacturing, and distribution of radiation technology and isotopes for medical, scientific, and industrial applications
- The company markets Yttriga, an Yttrium Chloride sterile solution that is registered as a medicinal product in the EU
- In November 2024, Eckert & Ziegler received EC approval for Theralugand Lutetium-177 Chloride
11. Jubilant Pharmova
Market Cap: 1.63B
Founded Year: 1978
Total Employees: 3,618
Headquarters: Uttar Pradesh, India
Stock Exchange: NSE
- Jubilant Pharmova is a global pharmaceutical company that is part of the Jubilant Life Sciences Group. The company operates into three segments: Specialty Pharmaceuticals (Radiopharmaceuticals), Allergy Therapy Products and CDMO
- HICON and RUBY-FILL are among the various radiopharmaceutical products that the company offers
- In October 2024, Jubilant Radiopharma and Life Molecular Imaging entered into a strategic collaboration and licensing agreement to provide and distribute Neuraceq in Alabama
10. PeptiDream
Market Cap: 1.84B
Founded Year: 2006
Total Employees: 732
Headquarters: Kanagawa, Japan
Stock Exchange: TYO
- PeptiDream is a biotechnology company focused on the discovery and development of peptide-based therapeutics by leveraging its proprietary platform: Peptide Discovery Platform System (PDPS)
- 64Cu-ATSM is the lead asset of the company that is being developed for malignant brain tumors in collaboration with LinqMed and prostate cancer with Curium
- In December 2024, Peptidream disclosed a new candidate PD-29875, a peptide-radioisotope conjugate targeting Claudin 18.2 (CLDN18.2)
9. Telix Pharmaceuticals
Market Cap: 5.86B
Founded Year: 2015
Total Employees: 535
Headquarters: Melbourne, Australia
Stock Exchange: ASX
- Telix Pharmaceuticals is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals for the diagnosis and treatment of cancer and other unmet needs
- The company markets Illuccix, a radiopharmaceutical product for PET scans in prostate cancer, and has several radiopharmaceutical candidates in development, including TLX592 (225Ac–RADmAb) and TLX250 (177Lu–girentuximab)
- In October 2024, the US FDA accepted the NDA for Telix’s TLX101-CDx (Pixclara) and granted priority review with a PDUFA action date of 26 April 2025
8. Lantheus
Market Cap: 6.74B
Founded Year: 1956
Total Employees: 808
Headquarters: Massachusetts, United States
Stock Exchange: NASDAQ
- Lantheus is a global radiopharmaceutical company specializing in the development, manufacturing, and commercialization of radio therapies and precision diagnostic products
- The company’s key products include PYLARIFY, DEFINITY and TECHNELITE
- In July 2024, Lantheus acquired Meilleur Technologies and added NAV-4694, a ß Amyloid PET Imaging Agent for Alzheimer’s Disease to its product portfolio
7. BWXT Medical (BWX Technologies)
Market Cap: 9.35B
Founded Year: 1867
Total Employees: 8,700
Headquarters: Virginia, United States
Stock Exchange: NYSE
- BWXT Medical is a division of BWX Technologies focused on the development and manufacturing of medical isotopes for diagnostic imaging and therapeutic applications
- The company markets Indium-111 Oxyquinoline Solution & Sodium Iodide I-123 Oral Solution with several other radiopharmaceuticals in its pipeline
- In July 2024, BWXT Medical and NorthStar Medical Radioisotopes entered into a Master Services Agreement to facilitate the production of actinium-225 (Ac-225)
6. Bayer
Market Cap: 24.14B
Founded Year: 1863
Total Employees: 92,815
Headquarters: Leverkusen, Germany
Stock Exchange: ETR
- Bayer is a global life science company that operates under three business segments: crop science, pharmaceuticals, and consumer health. The company’s therapeutic area focuses on cardiology, gynecology, diabetes, oncology, and ophthalmology
- Bayer markets Xofigo (radium Ra 223 dichloride), a radiopharmaceutical to treat prostate cancer that has spread to the bones (bone metastases) in adult men
- In February 2024, Bayer entered into a capacity reservation agreement with PanTera for the supply of actinium-225
5. GE Healthcare
Market Cap: 37.04B
Founded Year: 1994
Total Employees: 53,000
Headquarters: Illinois, United States
Stock Exchange: NASDAQ
- GE Healthcare is a global leader in medical technologies and healthcare solutions, specializing in delivering imaging, diagnostics, and patient monitoring systems
- The company develops several molecular imaging agents, including DaTscan, Vizamyl, and more
- In December 2024, GE HealthCare agreed to acquire full ownership of Nihon Medi-Physics by purchasing a 50% stake from Sumitomo Chemical
4. Siemens Healthineers
Market Cap: 61.38B
Founded Year: 1847
Total Employees: 73,100
Headquarters: Bavaria, Germany
Stock Exchange: ETR
- Siemens Healthineers is a global MedTech company that provides a wide range of healthcare solutions, including diagnostic imaging, laboratory diagnostics, and digital health services
- Siemens’ radiopharmaceutical portfolio includes Ammonia N13, Amyvid and more
- In December 2024, Siemens Healthineers acquired advanced accelerator applications molecular imaging from Novartis
3. RayzeBio (BMS)
Market Cap: 120.16B
Founded Year: 1887
Total Employees: 34,100
Headquarters: New York, United States
Stock Exchange: NYSE
- RayzeBio is a biotechnology company focused on developing targeted therapies for cancer, using radiopharmaceuticals
- Currently the company pipeline includes three radiopharmaceutical candidates: RYZ101, RYZ801, and RYZ811 being developed for various indications
- In June 2024, RayzeBio paused the P-III (ACTION-1) study evaluating RYZ101 due to an isotope shortage
2. Novartis
Market Cap: 233.78B
Founded Year: 1996
Total Employees: 75,883
Headquarters: Basel City, Switzerland
Stock Exchange: NYSE
- Novartis is a global healthcare company focused on the discovery, development, and commercialization of therapies in cardiovascular, renal, metabolic (CRM), immunology, neuroscience, and oncology
- Lutathera and Pluvicto are the two radiopharmaceutical products that company markets
- In November 2024, Novartis entered into a license and collaboration agreement with Ratio Therapeutics for SSTR2-targeting radiotherapeutic candidate for cancer\
1. Eli Lilly
Market Cap: 783.76B
Founded Year: 1876
Total Employees: 47,000
Headquarters: Indiana, United States
Stock Exchange: NYSE
- Eli Lilly is an American pharmaceutical company that specializes in bone and joint disease, cancer, cardiovascular disease, diabetes, endocrine illness, immunology, neurodegeneration, neurology, and pain management
- The company’s pipeline includes one radiopharmaceutical candidate: 225Ac-PSMA-62 PNT2001 that is being developed for prostate cancer
- In July 2024, Eli Lilly entered into a strategic agreement with Radionetics Oncology to advance Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals
Sources:
- Company Websites
- Press releases
- Google Finance
- OANDA
Related Post: Top 20 Radiopharma Companies of 2024 Based on Market Cap
